Objective Wesought to establish an association between sporadic Alzheimer' s disease (AD) and presenilin 1 (PSEN1) gene polymorphisms in the Japanese population. Methods A 5 kb fragment containing the putative promoter of the PSEN1gene for randomly selected control subjects wassubcloned into plasmid and sequenced to screen novel polymorphisms in this region. Patients and controls were genotyped for five polymorphic markers in the PSEN1 region. Wethen constructed haplotypes using the computer program HAPLO and compared the frequencies between cases and controls. Subjects A total of 189 AD cases (NINCDS-ADRDA criteria) and 240 controls were studied. Results Wediscovered a novel polymorphism with high heterozygosity on -4,752 of the PSEN1promoter region. A significant association was observed between the -4,752 C/T polymorphism and late-onset AD. The odds ratio for ADassociated with the CC vs non-CC genotype was 1.59 (95% CI=1.01-2.51), while that of £ 4 vs non-8 4 in APOE gene was ).
Introduction
Alzheimer's disease (AD) is the most commoncause of dementia in mid-to late-life. To date, four genes have been found to be associated with ADphenotypes including the amyloid precursor protein (APP) gene, the apolipoprotein E gene, the presenilin 1 (PSEN1) and the presenilin 2 (PSEN2) genes (1, 2) . The majority of familial ADcases are associated with PSEN1mutations. Several studies have reported that variation in the PSEN1promoter is associated with AD. However, most of the studies failed to show the relationship between its genotype and the risk of AD (3) (4) (5) (6) (7) (8) (9) (10) . Furthermore, no haplotype analysis has been reported to date. In addition to our previous paper on the association of T/G polymorphism at intron 8 of the PSEN1gene with late-onset AD(1 1), here we report an association between sporadic AD and PSEN1gene polymorphisms in the Japanese population using extended haplotype analysis.
Subjects and Methods

Subjec ts
The Ethics Committee of Ehime University School of Medicine approved the study protocol. Patients were selected on NINCDS-ADRDA criteria for probable AD (12) , and non-demented controls were rigorously evaluated for cognitive impairment using the Mini-Mental State Examination (13) . Blood samples were obtained with informed consent from subjects in the Kansai (Osaka and Hyogo) area of Japan. A total of 189 unrelated AD patients (66 early-onset and 123 late-onset AD) had been diagnosed previously, and 240 controls (outpatients or healthy volunteers) were selected for each patient and matched for sex, age (within 5-year age group) and place of residence as described elsewhere ( 14) .
Screening for polymorphisms in PSENl
DNAwas purified by means of standard phenol-chloroform extraction and ethanol precipitation ( 1 5) , from lymphocytes or lymphoblastoid cell lines ( 16) . Wesystematically screened the 5 kb upstream of exon 1A of PSEN1in 10 randomly selected control subjects by meansof polymerase chain reaction (PCR), subcloning into plasmid and direct sequencing. PCRprimers were designed on the basis of the PSEN1sequence (GenBank accession no. AF109907) to amplify ll fragments (data not shown), including 5 kb of the 5'-flanking region. The PCR products were purified using SUPRECá"-01(TAKARACo., Kyoto) and Centri-Sep Spin Columns (Princeton Separations Inc., Adelphia, NJ, US). Direct sequencing was carried out using fluorescent dideoxynucleotides in an automated sequencer (ABI PRISM310; PE Biosystems), and sequences were compared by SeqEdá" version 1.0.3 (ABI) to detect polymorphisms, which were confirmed by sequencing with reverse primers. In addition, microsatellite candidates were screened using a representative PSEN1genomic sequence. Other polymorphisms reported previously (6, 9, 17) or SNP database (SNP Consortium Ltd.: http://snp.cshl.org)
were also screened. A total of 13 polymorphismswere screened in our Japanese population (Table 1) .
Geno typing
Genotyping five polymorphisms (including two novel ones) ofPSEN1 was done using PCR-RFLP, GeneScan (ABI). Each method is shown in Table 2 . BecauseAPOE8 4 is a risk factor for AD, we also performed APOEgenotyping as described previously (14) . PCRwas carried out in a 10-|il reaction volume containing the standard reaction buffer (1.5 mMMgCl2, 50 mM Constructing haplotypes and statistical analysis Allele frequencies were estimated by direct gene counting. Significant differences in genotypes and allele frequencies between ADpatients and controls were evaluated using the %2 test, with a significance level of 0.05. The genotypic frequencies were compared with the values predicted by the assumption of the Hardy-Weinberg equilibrium in the sample. Values of p<0.05 were considered significant. Oddsratios were calculated with two-tailed p values and 95% confidence intervals. Maximum-likelihoodestimates of haplotype frequencies and their standard errors (jackknife method) were calculated from the multisite marker-typing data, by means of computer software, HAPLOprogram (18), which implements the expecta- Tables 1 and 2 . Haplo types Wefound a total of40 haplotypes and compared the 12 major haplotype frequencies between cases and controls. The distribution pattern was significantly different between them (nor- APOEe 4 (+), one or two copies of8 4; APOE8 4 (-), no copies ofe 4. 95% CI: confidence interval at 95% level. (Table 5 ). Because the sample size was small, wecould not evaluate each haplotype as a risk factor or a protective factor. As expected, strong linkage disequilibrium was observed between -4,752 C/T, -2,782 I/D and +556 G/C. Three patterns of haplotypes were seen (2-2-1, 1-2-2, and 1-1-2) for the three sites.
Discussion
Weperformed a high resolution haplotype analysis of the PSEN1gene. The aim of this study was to determine whether the PSEN1gene was associated with sporadic ADand, if so, where the causative site or markers were strongly linked. Our study had four major findings. First, we identified five polymorphisms of PSEN1in the Japanese population. Twoout of five were novel. Second, we clarified the association between -4,752 C/T and AD. The risk-increasing effect was smaller for -4,752 C than for APOE 8 4. Therefore, the PSEN1 gene confers susceptibility to AD, dependent on the APOEgene. Third, we identified the 12 major haplotypes of the PSEN1gene and determined their frequencies in ADand controls. Haplotype frequencies were significantly different between ADand controls.
Haplotype analysis has become increasingly important for the study of human disease, especially for establishing founder effects for disease alleles. The haplotype has greater power than any individual SNP to track an unobserved, but evolutionarily linked, variable site (22) . Such analysis has been applied to some gene loci; APOE(23), ACE (24) , and AGT (25) . The present study determined the PSEN1haplotype frequencies.
Wecould not confirm the association between the -280 C/G or -48 C/T SNP and AD, that was reported in Caucasians (9, 10) , because of the rarity of polymorphism in our Japanese subjects. Instead, we clarified the association between the -4,752 C/T SNP and AD. As both are located in the 5'-upstream region, they may be related to the regulation of gene expression. The -280 C/G alters or creates a cis element important for transcriptional activity in neurons. To date, -280 C/G appears to be a risk factor for AD. Wedo not knowwhether the 5'-upstream region polymorphism has any influence on the expression level of PSEN1. Another possibility is that other, not yet identified polymorphisms in the PSEN1region are responsible for the observed association with PSEN1. The normative function of PSEN1has not yet been completely defined. However, several lines of evidence suggest that it plays a direct or indirect role in the proteolytic processing of Notch and (3APP. In the absence of functional PSEN1 expression, there is failure of the final intra membranouscleavage of Notch, which follows ligand binding and liberates the C-terminus of Notch necessary for signal transduction. The other effect of loss of PSEN1function is failure of y-secretase cleavage of (3APP stubs generated by a-or (5-secretase. This results in a profound reduction in the secretion ofA(3 and the accumulation of C83 (oc-stubs) and C99 ((3-stubs) derivatives of a-or P-secretase cleavage, respectively. Morerecently, PSEN1has been implicated in the y-secretase activity that generates the C-terminus of A(3 peptides (26) . Further studies should concentrate on howPSEN1mutation plays a direct role in the pathogenesis ofAD.
Taken together, these studies suggest that genetic variants within the PSEN1regulatory region might be implicated in the pathogenesis of AD. Confirmatory studies in other large population-based samples are needed to clarify this issue.
